Portfolio company
Microbiotica
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops live bacterial therapeutics and biomarkers for patients with inflammatory bowel disease and advanced melanoma.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
mbiomics
This company develops live bacterial therapeutics and a microbiome profiling platform to treat patients with cancer and inflammatory bowel diseases.
KOBIOLABS
This company develops microbiome-derived therapeutics and live biotherapeutic products for patients with immune, metabolic, neurological and gastrointestinal diseases.
EnteroBiotix
This biopharmaceutical company develops orally administered microbial therapeutics for patients with gastrointestinal diseases, including irritable bowel syndrome and blood cancers.
MRM Health
This biopharmaceutical company develops microbiome-based live biotherapeutic products for patients with chronic inflammatory diseases and immune-oncology conditions.
Vedanta Biosciences
This company develops microbiome-based oral therapies using bacterial consortia to treat patients with gastrointestinal and immune-mediated diseases.
Enterbiotix
This company develops orally administered microbiome therapeutics to treat patients with gastrointestinal conditions including irritable bowel syndrome and liver cirrhosis.
Kanvas Biosciences
This company develops microbiome mapping platforms and live biotherapeutic products for pharmaceutical companies and research institutions focused on treating cancer and inflammatory diseases.
Enterome
This biopharmaceutical company develops microbiome-derived immunotherapies for patients with solid and liquid cancers, including non-Hodgkin lymphoma, and inflammatory diseases.